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altered During acute graft-versus-
host Disease
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Clare Lendrem1, Hildegard T. Greinix3 and Anne M. Dickinson1*
1 Haematological Sciences, Medical School, Newcastle University, Newcastle upon Tyne, UK, 2 Department of Internal 
Medicine I, Medical University of Vienna, Vienna, Austria, 3 Division of Hematology, Medical University of Graz, Graz, Austria
Acute graft-versus-host disease (aGvHD) is the most frequent and serious complication 
following hematopoietic stem cell transplantation (HSCT), with a high mortality rate. 
A clearer understanding of the molecular pathogenesis may allow for improved thera-
peutic options or guide personalized prophylactic protocols. Circulating microRNAs are 
expressed in body fluids and have recently been associated with the etiology of aGvHD, 
but global expression profiling in a HSCT setting is lacking. This study profiled expression 
of n = 799 mature microRNAs in patient serum, using the NanoString platform, to identify 
microRNAs that showed altered expression at aGvHD diagnosis. Selected microRNAs 
(n =  10) were replicated in independent cohorts of serum samples taken at aGvHD 
diagnosis (n = 42) and prior to disease onset (day 14 post-HSCT, n = 47) to assess 
their prognostic potential. Sera from patients without aGvHD were used as controls. 
Differential microRNAs were investigated in  silico for predicted networks and mRNA 
targets. Expression analysis identified 61 microRNAs that were differentially expressed at 
aGvHD diagnosis. miR-146a (p = 0.03), miR-30b-5p (p = 0.007), miR-374-5p (p = 0.02), 
miR-181a (p = 0.03), miR-20a (p = 0.03), and miR-15a (p = 0.03) were significantly 
verified in an independent cohort (n = 42). miR-146a (p = 0.01), miR-20a (p = 0.03), 
miR-18 (p = 0.03), miR-19a (p = 0.03), miR-19b (p = 0.01), and miR-451 (p = 0.01) 
were differentially expressed 14 days post-HSCT in patients who later developed aGvHD 
(n = 47). High miR-19b expression was associated with improved overall survival (OS) 
(p = 0.008), whereas high miR-20a and miR-30b-5p were associated with lower rates 
of non-relapse mortality (p = 0.05 and p = 0.008) and improved OS (p = 0.016 and 
p = 0.021). Pathway analysis associated the candidate microRNAs with hematological 
and inflammatory disease. Circulating biofluid microRNAs show altered expression at 
aGvHD onset and have the capacity to act as prognostic and diagnostic biomarkers. 
Their differential expression in serum suggests a role for circulatory microRNAs in aGvHD 
pathology, which warrants further investigation.
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highlighTs
•	 Comprehensive	 profiling	 identified	 61	 microRNAs	 that	
demonstrate	 significant	 differential	 expression	 at	 aGvHD	
onset.
•	 Differential	microRNAs	can	also	be	detected	at	day	14	post-
HSCT,	prior	to	disease	onset.
•	 High	 expression	 of	 miR-20a	 is	 associated	 with	 improved	
overall	survival	and	shows	promise	as	a	prognostic	indicator	
for	risk	of	developing	aGvHD.
•	 Dysregulated	microRNAs	are	predicted	to	target	key	pathways	
implicated	in	aGvHD	pathology.
inTrODUcTiOn
Over	40,000	hematopoietic	stem	cell	transplants	(HSCTs)	are	car-
ried	out	in	Europe	each	year	(1)	as	curative	treatment	for	a	range	
of	 hematological	 diseases,	 including	 leukemia	 and	 lymphoma.	
However,	up	to	40%	of	HSCT	patients	will	develop	graft-versus-
host	disease	 (GvHD)	 in	 either	 an	 acute	or	 a	 chronic	 form	 (2).	
Acute	GvHD	(aGvHD)	is	a	serious	complication	of	HSCT	and	
occurs	 when	 T  cells	 in	 the	 graft	 elicit	 an	 immune	 response	
against	 the	 host,	 causing	 tissue	 damage	 in	 the	 skin,	 liver,	 and	
gastrointestinal	tract	(2).	It	can	be	life	threatening	and	is	the	main	
cause	of	death	post-HSCT.	Currently,	there	are	no	validated	early	
diagnostic	or	predictive	markers	of	the	disease,	which	would	aid	
the	clinician	to	either	tailor	therapy	or	alter	therapeutic	regimens	
on	an	individual	basis	to	improve	outcome.
microRNAs	are	an	interesting	novel	class	of	biomarkers,	with	
potential	 clinical	 relevance.	 These	 small	 (22–25	 nucleotides),	
non-coding	 RNAs	 regulate	 gene	 expression	 by	 binding	 to	 the	
3′UTR	 and	 repressing	 translation.	Within	 the	 last	 decade,	 cir-
culating	microRNAs	have	been	identified	in	human	plasma	and	
serum	(3,	4),	where	they	are	resistant	to	RNase,	boiling,	changes	
in	pH,	extended	storage,	and	freeze–thaw	cycles	(5).	This	protec-
tion	 can	 be	 attributed	 to	 the	 packaging	 arrangements	 used	 to	
transport	microRNAs	to	various	body	systems.	microRNAs	can	
be	bound	by	 (i)	protection	proteins	 (such	as	nucleophosmin	1	
and	agonaute	2)	(6–8),	(ii)	lipid	or	lipoprotein	complexes	(includ-
ing	high-density	lipoprotein	and	low-density	lipoprotein),	or	(iii)	
encapsulated	into	extracellular	vesicles	such	as	exosomes	(9,	10).	
Together,	 these	 protein	 and	 vesicle	 chaperones	 allow	 selective	
export	of	microRNAs,	protecting	them	within	the	extracellular	
environment	(6).
Recently,	microRNAs	have	 gained	 added	 attention	 for	 their	
potential	 as	biomarkers	within	circulating	biofluids	as	 they	are	
robust,	 they	can	be	detected	by	defined	and	clinically	 translat-
able	technologies,	and	additionally,	biofluids	can	be	collected	in	
quantity	using	non-invasive	methods.	Despite	previous	interest	
focusing	 on	 circulating	 protein	 biomarkers	 (11),	 microRNAs	
may	 offer	 several	 advantages	 as	 they	 are	 lower	 in	 complexity,	
conserved	 among	 clinically	 relevant	 species,	 expressed	 specifi-
cally	in	different	tissues	or	biological	stages,	and	easily	measured	
using	common	laboratory	techniques	(12).
Preliminary	studies	have	assessed	expression	of	specific	circu-
lating	microRNAs	in	the	serum	or	plasma	of	patients	post-HSCT	
to	identify	potential	biomarkers	for	aGvHD	incidence,	severity,	
or	 outcome	 (13–17),	 and	 some	 investigations	 have	 included	
profiling	of	an	extended	microRNA	repertoire	(13,	17).	However,	
these	 studies	have	 focused	on	a	 subset	of	microRNAs	 that	 can	
be	detected	by	high-throughput	qRT-PCR-based	arrays	(13,	17)	
or	within	specific	subsets	of	patients	such	as	lymphoma	patients	
receiving	matched	unrelated	donor	(MUD)	allo-HSCT	(17).
Thus,	 comprehensive	 profiling	 of	 the	microRNA	expression	
spectrum	 in	 relation	 to	 aGvHD,	which	 takes	 into	 account	 the	
heterogeneity	of	the	HSCT	clinical	setting	including	underlying	
disease,	conditioning,	and	prophylaxis,	is	lacking.	Consequently,	
much	work	is	needed	to	reproducibly	identify	microRNAs	that	
are	deregulated	 in	aGvHD	and	validate	 these	findings	 in	 inde-
pendent	cohorts,	which	reflect	the	diversity	in	clinical	protocols	
employed	by	different	transplant	centers.
This	study	aimed	to	comprehensively	profile	n = 799	highly	
conserved	 mature	 human	 microRNAs	 in	 post-HSCT	 patient	
serum	 using	 NanoString	 nCounter	 technology,	 to	 explore	 the	
spectrum	of	microRNAs	demonstrating	differential	expression	at	
aGvHD	diagnosis.	This	provides	a	sensitive,	highly	multiplexed	
method	 for	 detecting	 direct	 digital	 counts	 of	 each	microRNA,	
without	 the	need	 for	 reverse	 transcription	or	 amplification.	To	
illustrate	the	prominence	of	microRNAs	differentially	expressed	
at	aGvHD	onset,	candidate	microRNAs	were	verified	and	 then	
further	explored	for	their	prognostic	potential	in	an	independent	
cohort.
MaTerials anD MeThODs
clinical cohorts and ethics
microRNA	expression	analysis	was	performed	for	n = 12	patients	
(aGvHD	n = 6,	no	aGvHD	n = 6)	undergoing	allogeneic	HSCT	at	
the	Medical	University	Hospital	Vienna	between	2010	and	2014	
(mean	diagnosis	35 days,	range	7–62 days)	(Table 1).	Replication	
and	expansion	of	NanoString	data	were	performed	on	two	inde-
pendent	 cohorts:	 diagnostic	 (n =  42)	 (collected	 at	 the	 time	 of	
aGvHD	diagnosis	or	equivalent	time	point	for	no	aGvHD	cases,	
±3 days)	(aGvHD	n = 24,	no	aGvHD	n = 18)	(mean	diagnosis	
29 days,	range	14–90 days)	or	prognostic	(n = 47)	(collected	on	
day	14	(D14)	post-HSCT)	(aGvHD	n = 24,	no	aGvHD	n = 23)	
(mean	 diagnosis	 41  days,	 range	 20–100  days)	 serum	 samples	
collected	from	allogeneic	HSCT	patients	undergoing	transplanta-
tion	between	2008	and	2014	at	the	Freeman	Hospital,	Newcastle	
upon	Tyne,	UK	(Table 2).
All	 patients	 consented	 for	 sample	 collection	 and	molecular	
testing,	and	the	project	was	approved	by	the	Newcastle	and	North	
Tyneside	I	Research	Ethics	Committee	and	the	Ethics	Committee	
of	the	Medical	University	of	Vienna,	Austria.	The	overall	clinical	
aGvHD	grade	was	 diagnosed	 by	 clinicians	 in	 accordance	with	
the	NIH	 consensus	 and	modified	Glucksberg	 criteria	 (18,	 19).	
All	the	clinical	data	were	obtained	from	the	EuroTransplantBank	
database.1	Investigations	were	conducted	in	accordance	with	the	
Helsinki	Declaration.
1	www.EuroTransplantBank.org.
Table 2 | clinical and outcome details of the diagnostic and prognostic cohorts.
Diagnostic cohort Prognostic cohort cohort comparison
all no gvhD, N (%) agvhD, N (%) p Value all no gvhD, N (%) agvhD, N (%) p Value p Value
All 42 18 24 47 23 24
Patient gendera
Male 27 (64) 11 (61) 16 (67) 0.75a 23 (49) 10 (43) 13 (54) 0.56a 0.20a
Female 15 (36) 7 (39) 8 (33) 24 (71) 13 (57) 11 (46)
Donor gendera
Male 32 (76) 14 (78) 18 (75) 1.0a 34 (72) 17 (74) 17 (71) 1.0a 0.81a
Female 10 (24) 4 (22) 6 (25) 13 (28) 6 (26) 7 (29)
Mean age 
(years)b
51 50 52 0.62b 49 49 49 0.98b 0.82b
Range (years) 20–65 26–61 20–65 20–69 24–68 20–69
relationshipa
MUD 36 (86) 14 (78) 22 (92) 0.38a 28 (60) 10 (43) 18 (75) 0.04a 0.02a
SIB 6 (14) 4 (22) 2 (8) 19 (40) 13 (56) 6 (25)
conditioninga
RIC 35 (83) 15 (83) 20 (83) 1.0a 20 (43) 19 (83) 16 (67) 0.32a 0.01a
Myeloablative 7 (17) 3 (17) 4 (17) 27 (57) 4 (17) 8 (33)
Outcomea
Alive 29 (69) 15 (83) 14 (58) 28 (60) 15 (65) 13 (54) 0.56a 0.38a
Dead 13 (31) 3 (17) 10 (42) 0.10a 19 (40) 8 (35) 11 (47)
Clinical details of the diagnostic (n = 42) (collected at the time of aGvHD diagnosis ±3 days) and prognostic (n = 47) (collected on day 14 post-HSCT) Newcastle cohorts to test 
for differences between aGvHD and no aGvHD groups and also between the diagnostic and prognostic cohorts. Outcome was evaluated from the date of death or the date last 
assessed in clinic.
p Values were calculated using the Fisher’s exact testa or independent two sample t-testb, as appropriate.
MUD, matched unrelated donor; SIB, sibling donor; RIC, reduced intensity conditioning; N, number; HSCT, hematopoietic stem cell transplantation; aGvHD, acute graft-versus-host 
disease.
Table 1 | clinical details of the nanostring cohort.
iD Disease 
status
Date Tx Patient age 
(years)
Patient 
gender
agvhD Proph Days onset 
agvhD
agvhD 
grading
sample day 
(post-hscT)
Dx Tx type cond
1 aGvHD 23/06/2014 52 F CSA + MMF 57 Skin II 57 CML MUD RIC
2 aGvHD 30/07/2014 33 M CSA + MMF 62 Skin II 62 AML MUD RIC
3 aGvHD 09/05/2014 56 F CSA + MMF 26 Skin II/GI II 26 MDS MUD RIC
4 aGvHD 10/06/2014 58 M CSA + MMF 23 Skin II 23 MDS SIB RIC
5 aGvHD 17/07/2014 51 F CSA 34 Skin III 34 AML MUD MYO
6 aGvHD 14/11/2014 27 M CSA + MTX 7 Skin II 7 MDS SIB RIC
7 No aGvHD 20/01/2010 57 M CSA + MTX N/A N/A 57 AML MUD RIC
8 No aGvHD 22/03/2013 60 M CSA + MMF N/A N/A 31 AML MUD RIC
9 No aGvHD 11/04/2013 41 M CSA + MMF N/A N/A 40 ALL-T MUD RIC
10 No aGvHD 05/07/2013 51 M CSA + MTX N/A N/A 45 CML SIB MYO
11a No aGvHD 17/01/2014 47 M CSA + MTX N/A N/A 38 AML MUD MYO
12 No aGvHD 04/04/2014 43 F CSA + MTX N/A N/A 40 AML SIB RIC
A total of 12 diagnostic serum samples taken from Vienna patients at aGvHD onset (n = 6) or from aGvHD-free controls (n = 6) were analyzed for microRNA expression using 
NanoString.
Tx, transplant; Proph, prophylaxis; Dx, diagnosis; Cond, conditioning; F, female; M, male; CSA, cyclosporine A; MMF, mycophenolate mofetil; MTX, methotrexate; GI, 
gastrointestinal; CMML, chronic myelomonocytic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; ALL-T, T-lineage acute lymphoblastic leukemia; CML, 
chronic myeloid leukemia; MUD, matched unrelated donor; SIB, sibling donor; RIC, reduced intensity conditioning; MYO, myeloablative conditioning; N/A, not applicable.
aSample removed from the final NanoString data analysis due to failed quality control parameters.
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serum rna isolation
Whole	 blood	 samples	were	 collected	 in	 7 ml	 vacutainers	 con-
taining	 no	 anticoagulant	 and	 left	 to	 clot,	 and	 the	 supernatant	
was	 centrifuged	 at	 500  g	 for	 5 min	 and	 then	 stored	 at	−80°C.	
Total	RNA	was	 isolated	 from	250 μl	aliquots	using	 the	Norgen	
Biotek	Total	RNA	kit,	 following	 the	supplier’s	 instructions.	For	
NanoString	profiling,	 the	RNA	isolated	from	4 × 250 μl	serum	
aliquots	was	concentrated	to	25 μl	by	pooling	replicate	RNA	isola-
tions	using	a	NanoString	Technologies-approved	centrifugation	
protocol,	incorporating	Amicon	Ultra-0.5	Centrifugal	Filter	Units	
(Merck	Millipore).	All	RNA	was	quantified	using	the	Bioanalyzer	
and	RNA	6000	Pico	kit	 (Agilent),	 and	 interassay	variation	was	
reported	as	7.21%.	Variation	in	RNA	recovery	between	samples	
was	 compensated	 for	 by	 the	 use	 of	NanoString	 and	 qRT-PCR	
endogenous	controls.
nanostring microrna Profiling
Total	RNA	was	profiled	using	the	nCounter®	Human	v3.0	miRNA	
Expression	 Assay	 Kit	 (NanoString	 Technologies),	 based	 on	
miRBase	v21.	The	code	set	incorporated	799	mature	microRNAs	
4Crossland et al. Serum microRNA Expression in aGvHD
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and	included	6	positive	controls,	8	negative	controls,	6	 ligation	
controls,	 and	 5	 mRNA	 housekeeping	 controls	 (ACTB,	 B2M,	
GAPDH,	RPL19	 and	RPLP0).	 Starting	material	 comprised	3 μl	
of	concentrated	serum	RNA.	Data	normalization	was	performed	
using	nSolver	Analysis	Software	v2.5	(NanoString	Technologies),	
with	code	set	content	normalization	to	the	top	100	microRNAs	
established	using	geometric	means.
TaqMan microrna analysis
Individual	microRNAs	were	evaluated	in	independent	diagnostic	
and	prognostic	cohorts	by	TaqMan	qRT-PCR.	Briefly,	microRNA	
and	endogenous	control	[HY3	and	U6	(20)]	specific	cDNA	was	
generated	using	TaqMan®	Assays	and	the	TaqMan®	microRNA	
Reverse	Transcription	kit	 (Life	Technologies),	 according	 to	 the	
supplier’s	protocol.	Each	15 μl	 reaction	 incorporated	4 μl	 total	
RNA.	 Quantitative	 RT-PCR	 was	 performed	 incorporating	
SensiFast	 Probe	Hi-Rox	 reagent	 (Bioline).	 Each	 10 μl	 reaction	
incorporated	3.25 μl	cDNA,	and	thermal	cycling	was	performed	
in	 triplicate	 using	 the	 7900HT	 Real-Time	 PCR	 System	 (Life	
Technologies),	 according	 to	 manufacturer’s	 recommended	
conditions.	The	interassay	and	intraassay	variation	were	reported	
for	 an	 example	 microRNA	 (miR-15a:	 interassay  =  1.89%,	
intraassay =  2.26%)	 for	 proof	 of	 principle	 of	 the	 quantitative	
performance	of	qRT-PCR	(Table	S1	in	Supplementary	Material).	
In	addition,	an	example	microRNA	(miR-146a)	was	assessed	in	
normal	healthy	controls	(n = 3),	 in	 triplicate	 technical	repeats,	
across	three	consecutive	time	points	(Day	1–3),	to	demonstrate	
stability	of	microRNA	expression	across	repetitive	measurements	
(Figure	S1	in	Supplementary	Material).
ingenuity Pathway analysis
The	 biological	 targets	 of	 identified	 microRNAs	 were	 investi-
gated	 using	 QIAGEN’s	 Ingenuity®	 Pathway	 Analysis	 (IPA®).2	
Interactions	 and	 networks	 between	 significant	 genes	 and	
microRNAs	were	mapped	to	pathways,	regulators,	diseases,	and	
functions	based	on	direct/indirect	and	experimentally	validated	
targets.
statistical analysis
For	 NanoString	 analysis,	 fold	 change	 (FC)	 expression	 differ-
ences	 between	 two	 groups	 were	 calculated	 using	 nSolver	 v2.5	
(NanoString	Technologies)	ratio	data,	based	on	normalized	count	
data.	Further	analysis	was	performed	using	a	pipeline	designed	
by	Newcastle	University,	Haematological	Sciences	Department.	
This	integrated	a	number	of	“R”	(R	project)	statistical	packages	
in	the	“R”	programming	language.	p	Values	between	two	groups	
were	 generated	 using	 a	 two-tailed	 t-test.	 Volcano	 plots	 were	
generated	using	functions	within	the	“ggplot2”	(v2.1.0)	package,	
and	 heatmaps	 were	 constructed	 using	 “gplots”	 (v2.17.0)	 and	
“RColorBrewer”	 (v1.1-2),	 based	on	 an	unsupervised	 clustering	
approach	of	the	normalized	expression	counts,	with	a	Euclidean	
2	www.ingenuity.com.
(L2	norm)	distance	measure	and	“Complete”	as	the	agglomera-
tion	method.	Quantitative	 RT-PCR	microRNA	 expression	was	
assessed	using	SDS2.4	software	(Life	Technologies)	and	analyzed	
using	 GraphPad	 Prism	 v6.0,	 SPSS	 v22.0	 and	 SigmaPlot	 v12.5.	
Differences	between	groups	were	assessed	using	the	independent	
or	paired	t-test	(two	groups)	or	one-way	ANOVA.	Receiver	oper-
ating	characteristic	(ROC)	analysis	was	performed	using	disease	
or	survival	status	as	the	binary	state	(classification)	variable	and	
marker	expression	on	a	continuous	scale	as	 the	 test	variable	 to	
determine	area	under	 the	curve	 (AUC)	(SigmaPlot	v12.5).	The	
ROC	posttest	results	used	a	pretest	prior-probability	of	aGvHD	of	
0.5	and	cost	ratio	of	1.0	(21).	Overall	survival	(OS)	was	calculated	
using	the	time	in	years	from	transplant	to	death	or	last	follow-up.	
Survival	plots	were	generated	using	the	Kaplan–Meier	method,	
and	differences	in	outcome	were	assessed	for	significance	using	
the	 Log-Rank	 test	 (SPSS	 v22).	 The	 threshold	 to	 determine	
dichotomies	for	microRNA	expression	(low	and	high	expression)	
was	evaluated	by	ROC	analysis.	Cumulative	incidence	based	on	
the	competing	risk	method,	as	described	by	Fine	and	Gray	(22),	
was	used	for	assessing	the	association	between	microRNAs	and	
both	 relapse	 and	 non-relapse	mortality	 (NRM)	 (23)	 using	 “R”	
package	“cmprsk”	(competing	risks)	(24).	To	test	for	confound-
ing	 variables,	 each	 clinical	 variable	 for	 which	 data	 were	 avail-
able	was	added	to	the	model	(Cox	Regression),	and	the	hazard	
ratio	was	assessed	for	>10%	difference,	after	adjusting	for	each	
variable.	Correlation	between	microRNA	expression	 levels	was	
determined	 using	 Pearson’s	 correlation	with	Holm–Bonferroni	
multiple	comparisons	adjustment	applied	(25).
resUlTs
clinical Details of the cohorts
NanoString	microRNA	 expression	 profiling	was	 performed	 on	
serum	samples	 taken	 from	12	adult	 (mean	age	48 years,	 range	
27–60  years)	 allo-HSCT	 patients	 transplanted	 between	 2010	
and	 2014	 at	 the	 Department	 of	 Internal	 Medicine	 I,	 Medical	
University	of	Vienna,	Austria	(Table 1).	There	were	n = 8	MUD,	
n = 4	sibling,	n = 9	reduced	intensity,	and	n = 3	myeloablative	
transplants.	There	were	four	female	and	eight	male	patients	and	
aGvHD	 prophylaxis	 included	 cyclosporine  ±  mycophenolate	
mofetil	or	methotrexate.	Six	patients	showed	clinical	symptoms	
of	 aGvHD	at	 the	 time	of	 sample	 collection	 (skin	 II–III	 and/or	
gastrointestinal	II),	with	a	mean	time	of	onset	of	35 days	(range	
7–62 days	post-HSCT),	while	six	were	aGvHD	free	(Table 1).
Verification	 of	 NanoString	 results	 was	 performed	 using	
a	 diagnostic	 cohort	 (n  =  42)	 of	 serum	 samples	 taken	 from	
patients	at	the	onset	of	aGvHD	symptoms	(mean	29 days,	range	
14–90  days	 post-HSCT)	 who	 were	 transplanted	 at	 a	 separate	
European	Institution	(Newcastle)	(Table 2).	As	conditioning	and	
prophylaxis	 regimens	 can	 be	 highly	 heterogeneous	 according	
to	the	transplant	center,	replication	in	an	independent	cohort	is	
essential	to	identity	microRNAs	that	are	differentially	expressed	in	
aGvHD	serum,	regardless	of	the	transplant	protocols.	The	cohort	
comprised	n = 18	(43%)	no	aGvHD	and	n = 24	(57%)	aGvHD	
(grade	 II	n =  22,	grade	 III	n =  2)	HSCT	patients	 transplanted	
between	2011	and	2014.	Clinical	presentation	included	skin	only	
5Crossland et al. Serum microRNA Expression in aGvHD
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(n = 15),	skin	and	intestine	(n = 2),	skin	and	liver	(n = 1),	and	
liver	only	(n = 1),	while	the	sites	of	aGvHD	manifestation	were	
unknown	for	n = 5	patients.	Transplants	included	both	reduced	
intensity	 conditioning	 (RIC)/myeloablative	 and	 MUD/sibling	
donor	 (SIB)	 relationships	 (Table  2).	There	 was	 no	 significant	
difference	in	patient	gender	(p = 0.75),	donor	gender	(p = 1.0),	
age	(p = 0.62),	relationship	to	donor	(p = 0.38),	or	conditioning	
regimen	(p = 1.0)	between	those	who	developed	aGvHD	vs.	no	
aGvHD	(Table 2).	Similarly,	there	was	no	significant	difference	
in	patient	gender	(p = 0.10),	age	(p = 0.31),	relationship	to	donor	
(p  =  0.23),	 or	 conditioning	 regimen	 (p  =  0.24)	 between	 the	
NanoString	(n = 12)	and	verification	diagnostic	(n = 42)	cohorts.	
The	presence	of	aGvHD	was	associated	with	clinical	outcome	in	
the	cohort	(NRM	p = 0.053).
To	 further	 explore	 the	 biomarker	 potential	 of	 NanoString	
identified	microRNAs,	 selected	microRNAs	were	 also	 assessed	
in	 a	 prognostic	 cohort	 (n =  47)	 of	 serum	 samples	 taken	 from	
HSCT	patients	at	D14	posttransplant,	from	the	same	center	as	the	
diagnostic	cohort	(Newcastle),	prior	to	the	onset	of	aGvHD	(no	
patients	had	aGvHD	at	the	time	of	sampling;	mean	aGvHD	onset	
41 days,	range	20–100 days	post-HSCT).	The	prognostic	cohort	
comprised	n = 23	(49%)	no	aGvHD	and	n = 24	(51%)	aGvHD	
(grade	II	n = 22,	grade	III	n = 2)	patients	transplanted	between	
2008	and	2013	in	Newcastle	(Table 2).	There	was	no	significant	
difference	in	patient	gender	(p = 0.56),	donor	gender	(p = 1.0),	
age	 (p  =  0.98),	 or	 conditioning	 regimen	 (p  =  0.32)	 between	
patients	 who	 later	 developed	 aGvHD	 vs.	 those	 who	 remained	
disease	free.	There	was	a	significant	(p = 0.04)	baseline	difference	
between	aGvHD	vs.	disease-free	patients	for	transplant	relation-
ship:	there	was	a	higher	percentage	of	aGvHD	patients	who	were	
MUD	 transplanted	 compared	 to	 those	 who	 were	 disease	 free,	
and	 there	was	also	a	higher	percentage	of	disease-free	patients	
who	were	 SIB	 transplanted	 compared	 to	 those	who	developed	
aGvHD	 (Table  2).	 However,	 when	 we	 adjusted	 for	 transplant	
relationship	 in	 a	 logistic	 model	 with	 aGvHD	 as	 the	 response,	
the	relationship	between	microRNA	and	aGvHD	was	unaffected	
(data	not	shown).	There	was	no	significant	difference	in	patient	
gender	(p = 0.20)	or	age	(p = 0.82)	between	the	diagnostic	and	
prognostic	 cohorts;	 however,	 there	was	 a	 higher	 percentage	 of	
SIB	transplants	and	myeloablative	conditioning	in	the	prognostic	
cohort	compared	to	the	diagnostic	cohort	(Table 2).	There	was	no	
significant	difference	in	clinical	outcome	between	the	diagnostic	
and	prognostic	cohorts	(p = 0.38)	(Table 2).
microrna expression analysis at agvhD 
Diagnosis
NanoString	 results	 for	 one	 sample	 (patient	 number	 11,	 no	
aGvHD)	demonstrated	poor	data	normalization	and	thus	did	not	
pass	quality	 control	parameters.	 Subsequently,	 this	 sample	was	
excluded	from	further	analysis.
All	 799	 target	microRNAs	 of	 the	 code	 set	were	 detected	 in	
n =  11	 serum	samples	assessed,	and	unsupervised	hierarchical	
clustering	analysis	was	able	to	clearly	separate	aGvHD	and	non-
aGvHD	patients.	A	total	of	n = 61	microRNAs	were	significantly	
differentially	expressed	in	aGvHD	(n = 6)	compared	to	no	aGvHD	
(n = 5),	of	which	n = 27	were	downregulated	(FC	−6.94	to	−1.75;	
p < 0.01	to	p = 0.048)	in	aGvHD,	while	n = 34	were	upregulated	
(FC	1.35–5.41;	p < 0.01	to	p = 0.046)	(Table	S2	in	Supplementary	
Material)	(Figures 1A,B).
replication of Differential microrna 
expression at agvhD Diagnosis
To	verify	the	NanoString	data,	10	microRNAs	(miR-146a,	miR-
30b-5p,	 miR-374-5p,	 miR-20a,	 miR-15a,	 miR-181a,	 miR-18a,	
miR-19a,	 miR-19b,	 and	 miR-451a)	 were	 selected	 for	 further	
assessment	 in	 the	 diagnostic	 verification	 cohort	 (Table  2),	
based	on	 those	with	high	FC	 and/or	 reported	 in	 the	 literature	
to	be	implicated	in	GvHD,	T-cell	function,	or	the	inflammatory	
response	(13,	26–32).
Expression	of	miR-146a	(p = 0.03),	miR-30b-5p	(p = 0.007),	
miR-374-5p	 (p =  0.02),	 and	miR-181a	 (p =  0.03)	 was	 signifi-
cantly	downregulated,	whereas	miR-20a	(p = 0.03)	and	miR-15a	
(p = 0.03)	were	significantly	upregulated	in	aGvHD,	in	agreement	
with	NanoString	data	(Figures 2A,B).	miR-18a	was	also	upregu-
lated	 in	 aGvHD,	 but	 not	 significantly	 (p =  0.06)	 (Figure  2B).	
There	 was	 no	 differential	 expression	 of	 miR-19a	 (p  =  0.50),	
miR-19b	(p = 0.95),	or	miR-451a	(p = 0.24)	(Figure 2B).	miR-
30b-5p	 (AUC =  0.75,	 p =  0.007),	 miR-374-5p	 (AUC =  0.74,	
p = 0.01),	and	miR-15a	(AUC = 0.70,	p = 0.04)	had	diagnostic	
utility	for	aGvHD	as	assessed	by	ROC	analysis,	whereas	miR-181	
(AUC = 0.68,	p = 0.06),	miR-146a	(AUC = 0.66,	p = 0.09),	and	
miR-20a	(AUC = 0.68,	p = 0.06)	were	approaching	significance	
(Figure 3).	Two-sample	t-tests	were	performed	to	check	for	base-
line	differences	in	microRNA	expression	between	aGvHD	and	no	
aGvHD	groups	 for	 transplant	 relationship,	 patient	 gender,	 and	
conditioning	(data	not	shown).	Although	some	of	the	tests	gave	
borderline-significant	 results,	 these	 were	 not	 consistent	 across	
cohorts,	so	it	is	unlikely	that	any	differences	in	the	microRNAs	
are	caused	by	clinical	factors.
correlations between micrornas at 
agvhD Diagnosis
Correlation	 analysis	 was	 performed	 between	 all	 candidate	
microRNAs	 assessed	 in	 the	 diagnostic	 verification	 cohort.	The	
majority	 of	 the	 microRNAs	 demonstrated	 significant	 positive	
correlation	(Table	S3	in	Supplementary	Material).	miR-19b	(eight	
correlations,	p < 0.01	to	p = 0.011),	miR-15a	(eight	correlations,	
p < 0.01	to	p = 0.025),	and	miR-19a	(eight	correlations,	p < 0.01	
to	p = 0.044)	were	the	most	highly	correlated	microRNAs,	fol-
lowed	by	miR-181	(six	correlations,	p < 0.01	to	p = 0.044),	miR-
374-5p	(six	correlations,	p < 0.01	to	p = 0.014),	miR-30b-5p	(six	
correlations,	p < 0.01	to	p = 0.005),	miR-18a	(five	correlations,	
p < 0.01	 to	p = 0.025),	miR-451	(five	correlations,	p < 0.01	 to	
p = 0.016),	miR-20a	(four	correlations,	p < 0.01	to	p = 0.002),	and	
miR-146a	(four	correlations,	p < 0.01	to	p = 0.001)	(Table	S3	in	
Supplementary	Material).
association between micrornas 
Differentially expressed at agvhD 
Diagnosis and clinical Outcome
The	10	microRNAs	 that	were	 selected	 for	 analysis	 in	 the	diag-
nostic	 certification	 cohort	 were	 assessed	 for	 association	 with	
clinical	outcome	(OS	and	NRM).	High	expression	of	miR-19b	was	
FigUre 1 | nanostring-detected fold changes (Fcs) in microrna quantity between acute graft-versus- host disease (agvhD) vs. no agvhD 
patients. Eleven allohematopoietic stem cell transplantation patient serum samples (six aGvHD and five no aGvHD) were included in the final data set for 
microRNA expression assessment (n = 799) using the NanoString microRNA panel. (a) Volcano plot to show the relationship between FC and significance 
between the two groups. A FC comparison was made comparing aGvHD to no aGvHD. The horizontal dashed line indicates cutoff for significance p < 0.05 
(−log10 p > 1.3) and the vertical lines for FC ≥ 1.5/≤−1.5. (b) Heatmap showing hierarchical clustering of significantly differentially expressed microRNAs 
(p < 0.05, n = 61), based on normalized digital expression counts, in serum samples between patients with aGvHD vs. no aGvHD. Each column represents an 
individual patient. Relative expression changes are indicated by the color scale (red: high; blue: low). No aGvHD (none) cases are indicated in gray, while aGvHD 
cases (GvH) are indicated in black.
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significantly	associated	with	improved	OS	(p = 0.008)	(Figure 4A),	
but	 showed	no	 association	with	NRM	(p =  0.94)	 (Figure  4B).	
Elevated	expression	of	miR-20a	and	miR-30b-5p	was	significantly	
associated	with	improved	OS	(p = 0.016	and	p = 0.021,	respec-
tively)	 (Figure  4A)	 and	 lower	NRM	 (p =  0.05	 and	p =  0.008,	
respectively)	(Figure 4B).	Statistical	modeling	to	adjust	for	con-
founding	variables	was	performed,	by	adding	each	clinical	vari-
able	for	which	clinical	data	were	available	(aGvHD	grade,	patient	
age,	conditioning	regimen,	donor	relationship,	donor	gender,	and	
patient	gender)	to	the	model	as	a	potential	confounding	variable.	
In	 each	 case,	 the	 hazard	 ratio	 after	 adjusting	 for	 each	 variable	
did	not	differ	by	>10%,	 indicating	a	 true	 relationship	between	
expression	of	the	microRNA	and	NRM.
Differential microrna expression prior to 
agvhD Diagnosis
The	same	10	microRNAs	were	also	assessed	at	D14	post-HSCT,	
prior	 to	 disease	 onset,	 in	 an	 independent	 prognostic	 cohort	
(Table  2)	 to	 investigate	 their	 prognostic	 biomarker	 potential.	
miR-146a	 (p = 0.01),	miR-20a	 (p = 0.03),	miR-18a	 (p = 0.03),	
miR-19a	(p = 0.03),	miR-19b	(p = 0.01),	and	miR-451	(p = 0.01)	
were	 expressed	 at	 significantly	 higher	 levels	 in	 patients	 who	
went	on	to	develop	aGvHD	vs.	no	aGvHD	(Figure 5A).	In	ROC	
analysis,	 miR-146a	 (A =  0.68,	 p =  0.03),	 miR-19b	 (A =  0.70,	
p = 0.02),	and	miR-451	(A = 0.69,	p = 0.03)	had	diagnostic	ability	
with	regards	to	aGvHD	incidence,	whereas	miR-18a	(A = 0.65,	
p = 0.09),	miR-19a	(A = 0.65,	p = 0.08),	and	miR-20	(A = 0.67,	
p = 0.06)	were	approaching	significance	(Figure 5B).	microRNA	
expression	at	D14	was	assessed	for	prediction	of	HSCT	outcome;	
however,	no	microRNAs	were	significantly	associated	with	OS	or	
NRM	(p > 0.05,	data	not	shown).
comparison of microrna expression 
between Prognostic and Diagnostic Time 
Points
Expression	of	candidate	microRNAs	was	compared	between	the	
time	of	onset	samples	of	the	diagnostic	cohort	(n = 42)	and	earlier	
D14	time	points	of	the	prognostic	cohort	(n = 47),	according	to	
aGvHD	 incidence.	 For	 both	 aGvHD	 and	 no	 aGvHD	 groups,	
expression	 levels	of	all	microRNAs	were	significantly	higher	 in	
the	 diagnostic	 cohort	 compared	 to	 the	D14	 prognostic	 cohort	
(p = <  0.001	 to	 0.006),	 except	 for	miR-18a	 and	miR-451a	 (no	
significant	increase,	p = 0.55–0.98)	and	miR-30b-5p	and	miR-15a	
(no	significant	increase	in	the	aGvHD	patient	group,	p = 0.06)	
(Figure 6).
Pathway analysis of Differential 
micrornas at agvhD Diagnosis
Candidate	 microRNAs	 identified	 by	 NanoString	 analysis	 were	
assessed	 for	 identification	 of	 potential	 target	 genes.	 This	 is	 a	
complex	undertaking,	due	to	the	short	nature	of	seed	sequence	
FigUre 2 | Differential microrna expression in the diagnostic verification cohort. Expression of the candidate microRNAs was assessed by qRT-PCR at 
the onset of acute graft-versus- host disease (aGvHD) symptoms in serum samples of the diagnostic verification cohort (n = 42) and analyzed according to aGvHD 
incidence. (a) Verification of microRNAs that were downregulated at aGvHD onset according to NanoString analysis. (b) Verification of microRNAs that were 
upregulated at aGvHD onset according to NanoString analysis. Box plot whiskers represent minimum to maximum expression, and p Values were calculated using 
the independent two sample t-test.
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regions	 being	 complementary	 to	 multiple	 target	 genes.	 Thus,	
Ingenuity	Pathway	Analysis	was	used	to	identify	genes	and	clas-
sify	targets	into	networks	and	pathways.	Results	indicated	direct	
or	 indirect	 involvement	of	15	of	61	microRNAs	 in	 the	“cancer,	
hematological	disease,	immunological	disease”	pathway,	includ-
ing	miR-146a	and	miR-18a	of	the	verification	microRNAs,	14	of	
61	in	the	“organismal	injury	and	inflammatory	disease”	pathway,	
including	miR-181a	and	miR-19b	of	the	verification	microRNAs	
and	11	of	61	in	the	“cancer,	connective	tissue	disorder,	organismal	
injury	 and	 abnormalities”	 pathway,	 including	miR-451a	 of	 the	
verification	microRNAs	(Figure	S2	in	Supplementary	Material).	
With	respect	to	diseases	and	functions,	5	of	61	microRNAs	were	
associated	 with	 inflammatory	 disease	 (miR-18a,	 miR-17-5p,	
miR-146a,	 miR-19b,	 and	 miR-92a),	 whereas	 19	 of	 61	 were	
involved	 in	 the	 inflammatory	 response	 (miR-181,	miR-185-5p,	
miR-18a,	miR-193a-3p,	miR-199,	miR-19b,	miR-30c,	miR-320b,	
miR-425-5p,	miR-513a,	miR-92a,	 let-7a-5p,	miR-100a-5p,	miR-
124-3p,	miR-146,	and	miR-1285-3p).	With	regard	to	inflamma-
tory	response-associated	microRNAs,	the	gene	targets	SP1, FOS, 
DDX20, AGO2, TP53, RB1, E2F1-3, PTEN, MOV10, MYC,	and	
ZEBZ	were	experimentally	validated	or	highly	predicted.
DiscUssiOn
Despite	aGvHD	being	the	most	frequent	and	serious	complica-
tion	of	HSCT,	there	are	still	no	prognostic	or	diagnostic	molecu-
lar	biomarkers	that	are	routinely	used	in	the	clinic	to	inform	on	
treatment	decisions	and	patients	outcome.	This	may,	in	part,	be	
due	to	an	incomplete	understanding	of	the	molecular	biology	of	
the	disease,	which	has	precluded	more	personalized	approaches	
to	conditioning	and	prophylaxis	regimens.	Seminal	research	has	
previously	 identified	blood	proteins	 that	associate	with	clinical	
outcome,	 including	 albumin,	 IL-2	 receptor-α,	 tumor	 necrosis	
factor	 receptor	 1,	 hepatocyte	 growth	 factor,	 IL-8,	 elafin,	 and	
REG-3α	 (33–37).	However,	 these	biomarkers	cannot	differenti-
ate	between	GvHD	and	other	inflammatory	conditions,	and	thus,	
additional	circulating	molecules	that	may	further	improve	upon	
the	accuracy	and	efficiency	of	biomarker	panels	are	required.	This	
study	sought	to	globally	profile	the	expression	of	microRNAs	at	
aGvHD	diagnosis	in	the	serum	of	post-HSCT	patients,	to	identify	
microRNAs	that	demonstrate	differential	expression	at	the	onset	
of	disease	symptoms.	This	focus	on	circulating	microRNAs	will	
allow	for	an	understanding	of	molecules	that	may	be	biologically	
active	at	aGvHD	diagnosis,	as	well	as	further	assessed	for	their	
biomarker	potential.
Although	previous	groups	have	performed	microRNA	profil-
ing	post-HSCT,	these	studies	have	focused	on	specific	subgroups	
of	patients	or	a	 refined	signature	of	microRNAs	 limited	by	 the	
qRT-PCR	 technology	 used	 (13,	 17).	This	 study	 was	 based	 on	
NanoString	 technology,	which	 incorporates	 over	 700	 validated	
microRNA	targets	allowing	for	the	most	comprehensive	assess-
ment	of	circulating	microRNA	expression	in	a	HSCT	setting	to	
date.	 Results	 identified	 61	 microRNAs	 that	 were	 differentially	
expressed	between	patients	with	aGvHD	compared	to	those	who	
remained	disease	free.	Of	these,	10	were	selected	for	verification	
using	 qRT-PCR	 in	 independent	 cohorts	 of	 samples	 taken	 at	
diagnosis	and	prior	to	onset	of	symptoms	(day	14	post-HSCT),	
based	on	their	high	FC	values	or	prior	association	with	aGvHD	
or	the	immune	or	inflammatory	response.
In	 the	 diagnostic	 verification	 cohort	 (n  =  42),	 miR-146a,	
miR-30b-5p,	 miR-374-5p,	 and	 miR-181	 were	 significantly	
downregulated	at	 aGvHD	diagnosis	 compared	 to	patients	who	
remained	aGvHD	free.	miR-146a	is	one	of	the	more	widely	stud-
ied	microRNAs	with	respect	to	aGvHD.	Stickel	et al.	reported	its	
upregulation	in	T-cells	of	mice	developing	aGvHD	compared	to	
untreated	controls,	 and	 transplantation	of	miR-146a	 -/-	T-cells	
resulted	in	increased	aGvHD	severity	and	reduced	survival	(31).	
In	 this	 study,	 miR-146a	 expression	 was	 significantly	 higher	 at	
FigUre 3 | association between serum micrornas and acute graft-versus- host disease (agvhD) at diagnosis by receiver operating characteristic 
analysis. Expression of candidate microRNAs was assessed by qRT-PCR at aGvHD onset in the verification cohort (n = 42) and analyzed according to aGvHD 
incidence. Receiver operating characteristic curves detailing area under the curve (A), p value, sensitivity, and specificity are shown.
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aGvHD	 diagnosis	 compared	 to	 day	 14	 samples.	 Interestingly,	
Stickel	et al.	observed	downregulated	miR-146a	shortly	 follow-
ing	allo-HCT	in	mice	(day	2),	followed	by	upregulation	in	T-cells	
later	in	the	aGvHD	reaction	(days	6	and	12),	which	they	hypoth-
esized	may	be	a	rescue	mechanism	to	counteract	inflammation	
(31).	As	most	microRNAs	assessed	in	this	study	were	expressed	
at	 a	 lower	 level	 following	 HSCT,	 it	 may	 be	 hypothesized	 that	
their	 translation	 is	disrupted	by	 the	HSCT	procedure,	and	 this	
warrants	further	investigation.	miR-30b-5p	has	been	implicated	
in	the	acute	allograft	rejection	process,	whereby	expression	was	
downregulated	in	acute	rejection	(38),	which	is	in	keeping	with	
the	lower	levels	of	miR-30b-5p	observed	in	aGvHD	in	this	study.	
Little	is	known	about	the	role	of	miR-30b-5p	in	relation	to	HSCT,	
although	 it	has	been	 shown	 to	be	present	 in	 regulatory	T-cells	
(Tregs),	where	it	targets	eight	signaling	pathways	associated	with	
their	 function	 (39).	Expression	of	miR-374	has	been	 identified	
in	non-activated	natural	Tregs	(nTregs),	and	there	is	evidence	to	
suggest	that	nTregs	may	prevent	allograft	rejection	(40).	In	this	
context,	 it	may	 be	 surprising	 that	miR-374	 levels	 are	 lower	 at	
aGvHD	diagnosis;	however,	nTregs	comprise	just	5–10%	of	the	
circulating	 CD4+	 population,	 and	 pro-inflammatory	 cytokines	
released	during	the	acute	response	can	suppress	nTreg	function	
(41).	miR-181	acts	as	an	intrinsic	modulator	of	T-cell	sensitivity	
and	 selection	 (26),	 and	 in	 accordance	with	 the	 present	 results	
showing	lower	miR-181	expression	at	aGvHD	diagnosis,	BMT-
recipient	mice	transplanted	with	miR-181	negative	donor	T-cells	
demonstrate	accelerated	aGvHD	(42).
In	contrast,	in	the	diagnostic	verification	cohort,	expression	of	
miR-20a,	miR-18a,	miR-19a,	miR-19b,	and	miR-451	was	signifi-
cantly	upregulated	 in	aGvHD	patients.	These	microRNAs	were	
selected	 for	verification	as	 they	are	members	of	 the	miR-17-92	
cluster,	a	well	characterized	loci	that	plays	a	fundamental	role	in	
T-cell	differentiation,	survival,	and	function	as	well	as	autoimmune	
responses	 (43–45).	 In	 relation	 to	aGvHD,	 the	cluster	promotes	
CD4+	T-cell	activation	and	Th1	differentiation,	while	inhibiting	
Th2	and	 iTreg	differentiation	and	also	promoting	migration	of	
CD8	T-cells	 to	aGvHD	target	organs	(32).	Blockade	of	miR-17	
or	 miR-19b	 inhibits	 alloreactive	 T-cell	 expansion	 and	 IFN-γ	
FigUre 4 | association between serum micrornas and acute graft-versus- host disease (agvhD) clinical outcome. Expression of candidate microRNAs 
was assessed by qRT-PCR at aGvHD onset in the verification cohort (n = 42) and analyzed according to outcome. (a) Overall survival according to microRNA 
expression in relation to follow-up from time of transplant to event. p Values were calculated using the log-rank test. (b) Non-relapse mortality (NRM) according to 
microRNA expression in relation to time from transplant to event. Dichotomized microRNA expression in relation to relapse and NRM is depicted by dotted and solid 
black and gray lines, respectively. p Values were calculated according to the Fine and Gray competing risk method.
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production	and	prolonged	survival	in	GvHD	afflicted	mice	(32).	
Thus,	our	data	are	in	keeping	with	an	aGvHD-promoting	role	for	
the	cluster,	whereby	expression	of	its	members	was	significantly	
upregulated	at	aGvHD	diagnosis.	Interestingly,	the	same	micro-
RNAs	were	also	upregulated	prior	to	symptomatic	disease	(at	day	
14),	further	supporting	their	role	in	T-cell	response	to	alloantigens	
(32).	Although	the	function	of	miR-451	is	less	well	characterized,	
it	has	been	shown	to	repress	Myc	expression	(46)	and	indirectly	
inhibit	the	PI3K/AKT	pathway	(47),	which	regulates	several	key	
events	in	the	inflammatory	response	to	damage	(48).
In	addition	to	the	microRNAs	selected	in	this	study	for	fur-
ther	verification,	previous	studies	have	associated	other	micro-
RNAs	with	aGvHD.	In	a	seminal	study	in	2012,	Ranganathan	
et al.	showed	that	miR-155	is	upregulated	in	T-cells	from	mice	
developing	 GvHD	 following	 HSCT	 and	 the	 use	 of	 miR-155	
inhibitors	 decreased	 disease	 severity	 and	 prolonged	 survival	
(49);	however,	this	study	focused	on	microRNA	expression	in	
tissue.	Indeed,	although	Xiao	et al.	detected	serum	upregula-
tion	of	miR-155	in	aGvHD	patients,	expression	levels	were	the	
lowest	among	the	microRNA	candidates	examined,	and	thus,	
miR-155	was	excluded	from	their	final	aGvHD	signature	(13).	
Xie	et al.	detected	upregulation	of	miR-155	in	aGvHD	patient	
serum,	which	 also	 correlated	with	disease	 severity;	 however,	
this	study	was	restricted	to	a	Han	Chinese	population	(n = 64)	
(14).	Collectively,	the	findings	may	highlight	the	heterogene-
ous	 nature	 of	 microRNA	 expression	 that	 is	 both	 tissue	 and	
condition	 specific.	Thus,	 despite	 promising	 results	 in	 tissue	
(49),	 this	may	not	be	reflective	of	miR-155	expression	 in	 the	
circulation.
A	small	study	by	Sang	et al.	additionally	reported	upregula-
tion	 of	 miR-92b	 in	 serum	 samples	 at	 aGvHD	 onset,	 while	
miR-150	 and	 miR-181	 were	 significantly	 downregulated	 (15).	
Expression	 was	 also	 altered	 prior	 to	 symptomatic	 disease,	
indicating	potential	biomarker	potential	 for	predicting	disease	
incidence	(15).	The	difference	in	miR-181	expression	was	most	
pronounced	and	also	associated	with	disease	severity	(15).	In	this	
present	study,	miR-181	was	also	significantly	downregulated	in	
aGvHD	compared	 to	patients	who	 remained	aGvHD	free	 (FC	
−2.26,	p = 0.046).	miR-181a	has	been	shown	to	enhance	CD4+	
T  lymphocytes	 toward	Th2	and	Treg	differentiation,	by	 target-
ing	 IFN-γ,	 and	expression	 levels	 correlate	with	 IFN-γ	 protein,	
but	 not	 mRNA	 expression	 (15).	 Further	 in-depth	 analysis	 of	
FigUre 5 | continued
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FigUre 6 | Differential microrna expression between prognostic and diagnostic samples. Expression of the candidate microRNAs was compared 
between the diagnostic cohort (n = 42) and the day 14 prognostic cohort (n = 47) and analyzed according to acute graft-versus-host disease incidence. Box plot 
whiskers represent minimum to maximum expression, and p values were calculated between groups using the independent two sample t-test.
FigUre 5 | continued 
Differential microrna expression in the prognostic cohort. Expression of the candidate microRNAs was assessed by qRT-PCR at day 14 posthematopoietic 
stem cell transplantation in the validation prognostic cohort (n = 47) and analyzed according to acute graft-versus-host disease (aGvHD) incidence. (a) microRNA 
expression according to aGvHD vs. no GvHD. Box plot whiskers represent minimum to maximum expression, and p values were calculated using the independent 
two sample t-test. (b) Receiver operating characteristic curves for incidence of aGvHD to determine prognostic ability of microRNA expression. The area under the 
curve (A), p value, sensitivity, and specificity are shown.
11
Crossland et al. Serum microRNA Expression in aGvHD
Frontiers in Immunology | www.frontiersin.org March 2017 | Volume 8 | Article 308
miR-181a	 expression,	 including	 expansion	 to	 functional	 stud-
ies,	will	be	important	to	define	the	role	of	this	microRNA	in	the	
aGvHD	reaction.
With	regard	to	microRNA	profiling	in	a	HSCT	setting,	in	2013	
in	an	elegant	study,	Xiao	et al.	investigated	the	expression	of	345	
microRNAs	in	the	plasma	of	patients	with	aGvHD,	compared	to	
patients	with	no	aGvHD,	using	a	qRT-PCR	array	(13).	The	study	
focused	on	a	discovery	cohort	followed	by	a	training	cohort	and	
identified	a	final	 signature	of	 four	microRNAs	(miR-423,	miR-
199-3p,	miR-93*,	 and	miR-377)	 that	 significantly	predicted	 for	
aGvHD	at	6 weeks	post-HSCT,	prior	to	the	onset	of	symptoms.	
Furthermore,	the	model	was	associated	with	disease	severity	and	
poor	OS	 (13).	This	 study	 highlighted	 the	 potential	 of	 biofluid	
microRNAs	 as	 independent	markers	 for	 prediction,	 prognosis,	
and	diagnosis	of	GvHD.	Gimondi	et al.	also	profiled	circulating	
microRNA	 expression	 using	 a	 qRT-PCR-based	 platform	 (17).	
They	assessed	samples	collected	28 days	post-HSCT	and	detected	
113	 microRNAs,	 of	 which	 27	 could	 collectively	 discriminate	
between	 aGvHD	 vs.	 no	 aGvHD.	miR-194	 and	miR-518f	 were	
significantly	upregulated	in	patients	who	later	developed	aGvHD,	
and	 pathway	 prediction	 analysis	 identified	 these	 microRNAs	
to	 target	 critical	 pathways	 implicated	 in	 aGvHD	 pathogen-
esis	 (17).	 However,	 there	 was	 no	 verification	 cohort	 included	
in	 the	 investigation,	and	 the	authors	did	not	detect	differential	
expression	of	the	microRNAs	previously	reported	by	Xiao	et al.	
(13).	 Indeed,	although	expression	of	 the	Xiao	et al.	microRNA	
signature	was	disparate	between	aGvHD	and	no	aGvHD	groups	
in	 this	 study,	 this	did	not	 reach	significance.	When	comparing	
the	27	unique	microRNAs	formerly	identified	by	Gimondi	et al.,	
7	 (miR-374b/20a/185/191/30b)	 were	 also	 significantly	 associ-
ated	with	aGvHD	in	this	study,	while	no	statistically	significant	
overlap	was	 identified	 for	 the	 remaining	microRNAs.	The	 lack	
of	 reproducibility	 between	microRNA	profiling	 studies	 to	 date	
may	not	be	 surprising,	due	 to	 the	high	degree	of	 variability	 in	
factors	when	designing	and	performing	these	experiments,	which	
may	 be	 attributed	 to	 clinical	 (patient	 characteristics,	 sampling	
time	points,	and	type	of	body	fluid	analyzed),	technical	(sample	
preparation,	 microRNA	 profiling	 platform,	 and	 spectrum	 of	
microRNAs	 profiled),	 and	 analytical	 (normalization	 strategy)	
factors.
With	respect	to	clinical	characteristics,	the	patients	included	
in	this	study	comprised	a	mixed	population	of	underlying	disease,	
treatment	prophylaxis,	 and	conditioning	 regimen	 to	 reflect	 the	
diverse	population	of	HSCT	patients	who	develop	aGvHD.	Xiao	
et al.	used	a	similar	approach	(13);	however,	the	patients	in	the	
study	 by	Gimondi	 et  al.	 were	 restricted	 to	 lymphoma	 patients	
in	 complete	 remission	 undergoing	 RIC	 (17).	 In	 addition,	 dif-
ferent	 time	points	of	 sampling	were	used	 in	 these	 studies,	 and	
Xiao	 et  al.	 investigated	 plasma	 taken	 6  weeks	 posttransplant	
(10)	and	Gimondi	et al.	focused	on	day	+28	posttransplant	(17).	
Furthermore,	 although	 earlier	 studies	 concentrated	 on	 plasma	
(13,	17),	serum	was	assessed	in	this	study.	It	has	been	suggested	
that	because	serum	is	 free	of	anticoagulants	 such	as	heparin,	a	
potent	inhibitor	of	downstream	PCR	reactions,	it	may	favor	more	
consistent	measurements	(50).	In	addition,	serum	processing	is	
less	 likely	 to	 be	 affected	 by	 hemolysis	 than	 plasma,	 where	 the	
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release	of	red	blood	cell	and	platelet-specific	microRNAs	during	
processing	and	may	bias	results.
In	relation	to	technical	considerations,	substantial	variability	
can	be	attributed	to	the	RNA	extraction	method	and	microRNA	
profiling	technology	employed.	A	spin-column-based	approach	
was	used	in	this	study;	however,	it	was	not	dependent	on	phenol-
based	steps	used	in	the	previous	studies	(10,	24),	which	have	been	
associated	with	low	RNA	purity	leading	to	reproducibility	issues,	
as	well	 as	 selective	 loss	 of	 small	 RNA	molecules	with	 low	GC	
content	(51).	The	choice	of	microRNA	detection	platform	is	par-
ticularly	important	when	distinguishing	small	molecules	at	low	
abundance	and	with	high	 sequence	homology	 (52).	Xiao	 et  al.	
based	their	assessment	on	Sybr-green	dye,	which	lacks	specificity	
in	 comparison	 to	 the	 TaqMan	 low-density	 array	 employed	 by	
Gimondi	et al.	(17).	However,	qRT-PCR	is	still	reliant	on	reverse	
transcription	of	RNA	to	cDNA,	which	can	introduce	bias.	This	
study	 relied	on	NanoString	profiling,	which	 is	 based	on	direct	
hybridization	of	reporter	molecules	 to	RNA,	and	thus	removes	
the	need	for	reverse	transcription.	The	analysis	is	based	on	a	direct	
digital	 count	of	 tagged	 labeled	barcodes,	 eradicating	any	back-
ground	noise.	Indeed	NanoString	technology	has	been	shown	to	
have	greater	consistency	and	a	lower	risk	of	introducing	technical	
variation	due	to	fewer	sample	preparation	steps	in	comparison	to	
qRT-PCR	(53).	Finally,	the	qRT-PCR	arrays	previously	employed	
were	restricted	to	a	refined	number	of	target	molecules	[n = 345	
(13)	and	n = 377	(17)],	and	the	degree	of	overlap	between	targets	
assessed	in	both	studies	is	not	clear.	In	contrast,	miRNAs	included	
in	the	nCounter	Human	v3	miRNA	panel	(n = 799)	account	for	
greater	 than	95%	of	all	observed	sequencing	reads	 in	miRBase	
v21,	 thus	 providing	 a	 far	 broader	 spectrum	 of	 microRNAs	
assessed	that	is	not	biased	by	preprofiling	target	selection.
Finally,	analytical	variables	have	the	potential	to	bias	results,	
and	this	is	particularly	dependent	on	the	normalization	methods	
used	(54).	Some	level	of	correction	may	be	achieved	by	spiking	in	
synthetic	microRNAs	(55),	which	was	the	approach	used	by	Xiao	
et al.	(13);	however,	 this	method	does	not	account	for	 intrinsic	
biological	 variation	 (56).	 While	 Gimondi	 et  al.	 calculated	
reciprocal	 ratios	 of	 the	 microRNA	 expression	 levels	 (17),	 this	
study	incorporated	14	positive	and	negative	controls,	6	ligation	
controls,	5	mRNA	housekeeping	controls,	 and	a	normalization	
factor	based	on	the	geometric	mean	of	100	targets	with	the	high-
est	counts.
In	conclusion,	although	results	implicate	circulating	micro-
RNAs	 in	 the	pathology	of	aGvHD,	and	 their	utility	as	disease	
biomarkers	shows	great	promise,	these	studies	are	still	in	their	
infancy,	and	few	overlapping	targets	between	reports	have	been	
identified.	Much	work	is	needed	to	validate	the	findings	in	inde-
pendent	cohorts	that	fully	reflect	the	high	level	of	heterogeneity	
in	conditioning	and	prophylaxis	regimens	employed	by	different	
clinical	 centers.	This	 may	 be	 achieved	 through	 collaboration	
between	 research	 groups,	 focusing	 on	 standardization	 of	 the	
samples,	 protocols,	 and	 technologies	 used,	 which	 will	 greatly	
improve	 the	 reproducibility	 of	 findings	 allowing	 for	 extended	
validation	of	microRNAs	of	 interest.	The	ultimate	aim	will	be	
to	 diagnose	 GvHD	 and	 predict	 outcome	 before	 the	 onset	 of	
clinical	 symptoms,	 allowing	 for	 earlier	 therapy	 and	 personal-
ized	treatments	and	leading	to	reduced	mortality	and	morbidity	
outcomes.
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